Intuitive is the dominant public surgical robotics franchise and belongs in any serious robotics basket.
Side-by-side research view
Compare names across metrics and research quality
Use up to 4 U.S.-listed names from this dashboard to compare valuation, growth, cash flow, balance-sheet strength, and the curated investment case in one place.
1 stocks in current compare
4 max names side by side
25 shared metrics lined up
Build a compare set
Enter comma-separated tickers from the dashboard universe. Duplicate tickers are ignored automatically.
Price
$353.17
1D change
+2.24%
Market cap
$125.08B
Sector
Healthcare
| Metric | ISRG |
|---|---|
| Price | $353.17 |
| 1D Change | +2.24% |
| Market Cap | $125.08B |
| Enterprise Value | $116.43B |
| Trailing P/E | 39.7 |
| Forward P/E | 29.4 |
| PEG Ratio | 1.81x |
| Price / Sales | 11.3 |
| EV / Revenue | 10.6 |
| Revenue Growth | 18.5% |
| Earnings Growth | 26.5% |
| Gross Margin | 66.8% |
| Operating Margin | 33.7% |
| Net Margin | 28.4% |
| ROE | 17.4% |
| Free Cash Flow | — |
| FCF Margin | — |
| Debt / Equity | — |
| Current Ratio | 6.43x |
| Dividend Yield | 0.00% |
| Next Earnings | Oct 20, 2026 |
| Quarterly Revenue | $nan |
| Revenue QoQ | nan% |
| Quarterly Net Income | $nan |
| Net Income QoQ | nan% |
ISRG thesis lens
Surgical robotics leader
Why it could benefit
- Intuitive is the dominant public surgical robotics franchise and belongs in any serious robotics basket.
- Its installed base, procedure growth, and recurring instruments model create a stronger moat than most robotics names.
- This adds a high-quality medical robotics angle that is less tied to data-center spending or industrial cycles.
Moat / edge
- Large installed base and deep surgeon training ecosystem.
- Recurring revenue from instruments, accessories, and service.
- Years of lead time and brand strength in robotic-assisted surgery.
What to watch
- Procedure growth and system placements.
- Adoption of newer da Vinci platforms and adjacent products.
- Gross-margin resilience as the business scales.
Key risks
- Premium valuation can leave less room for execution misses.
- Hospital capital-spending cycles still matter.